恩替卡韦治疗和将恩替卡韦改用替诺福韦阿拉法酰胺富马酸

StephenW

Comparison of efficacy and safety of the treatment of entecavir and switching entecavir to tenofovir alafenamide fumarate in chronic hepatitis B: Long term effects of the prospective study
Satoru Hagiwara  1 , Naoshi Nishida  1 , Kazuomi Ueshima  1 , Akihiro Yoshida  1 , Yasunori Minami  1 , Masatoshi Kudo  1
Affiliations
Affiliation

    1
    Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.

    PMID: 33900663 DOI: 10.1111/hepr.13650

Abstract

Aim: Both entecavir (ETV) and tenofovir alafenamide fumarate (TAF) are widely administered for chronic hepatitis B (CHB) in Japan. Nonetheless, whether the efficacy of TAF in decreasing the hepatitis B surface antigen (HBsAg) level and its safety are superior to those of ETV remain unclear. This study aimed to report the long-term effects and safety of 96-week ETV and TAF administration in patients with CHB.

Methods: A prospective comparative observational study was conducted on the following two groups: patients with CHB who received continuous ETV administration (n = 32) and patients with CHB who were switched from ETV to TAF upon request (n = 48). HBsAg, urinary β2-microglobulin (β2MG)/creatinine (Cr), urinary N-acetyl-β-D-glucosaminidase (NAG)/Cr, serum alanine aminotransferase (ALT), estimated glomerular filtration rate (eGFR), and bone mineral density (lumbar spine and femur) at 96 weeks were compared.

Results: The two groups did not significantly differ with respect to mean age, male/female ratio, and rate of hepatitis B e antigen (HBeAg)-positive status. The mean changes in serum HBsAg level and eGFR at 96 weeks were not significantly different between the two groups. The β2MG/Cr and NAG/Cr levels at 96 weeks were similar between the two groups. Additionally, the bone mineral density of the lumbar spine and femur as well as the serum ALT did not significantly differ.

Conclusions: When compared with patients who received continuous ETV administration, those who were introduced to TAF after ETV exhibited similar effects in terms of the decrease in HBsAg level and safety. This article is protected by copyright. All rights reserved.

Keywords: N-acetyl-β-D-glucosaminidase; entecavir hydrate; hepatitis B virus; tenofovir alafenamide fumarate; tenofovir disoproxil fumarate.

This article is protected by copyright. All rights reserved.

StephenW

恩替卡韦治疗和将恩替卡韦改用替诺福韦阿拉法酰胺富马酸酯治疗慢性乙型肝炎的疗效和安全性比较：前瞻性研究的长期效果
ator原聪1，西田直志1，上岛一和1，吉田明博1，南安顺德1，工藤正敏1
隶属关系
联系

    1个
    日本大阪大学山金代大学医学院消化病学和肝病学系。

    PMID：33900663 DOI：10.1111 / hepr.13650

抽象的

目的：恩替卡韦（ETV）和替诺福韦阿拉芬酰胺富马酸酯（TAF）在日本广泛用于慢性乙型肝炎（CHB）。然而，尚不清楚TAF在降低乙型肝炎表面抗原（HBsAg）水平方面的功效及其安全性是否优于ETV。这项研究旨在报告96周ETV和TAF给药对CHB患者的长期疗效和安全性。

方法：对以下两组进行了前瞻性比较观察研究：连续接受ETV给药的CHB患者（n = 32）和应要求从ETV转换为TAF的CHB患者（n = 48）。 HBsAg，尿β2-微球蛋白（β2MG）/肌酐（Cr），尿N-乙酰基-β-D-氨基葡萄糖苷酶（NAG）/ Cr，血清丙氨酸氨基转移酶（ALT），估计的肾小球滤过率（eGFR）和骨矿物质密度比较96周时的腰椎和股骨。

结果：两组在平均年龄，男女比例和乙型肝炎e抗原（HBeAg）阳性率方面无显着差异。两组在96周时血清HBsAg和eGFR的平均变化无显着差异。两组在96周时的β2MG/ Cr和NAG / Cr水平相似。此外，腰椎和股骨的骨矿物质密度以及血清ALT没有显着差异。

结论：与连续接受ETV的患者相比，在ETV之后接受TAF的患者在降低HBsAg水平和安全性方面表现出相似的效果。本文受版权保护。版权所有。

关键词：N-乙酰基-β-D-氨基葡萄糖苷酶；恩替卡韦水合物；乙型肝炎病毒;替诺福韦阿拉芬酰胺富马酸酯;替诺福韦酯富马酸二甲吡唑酯。

本文受版权保护。版权所有。

小牡丹

实事求是，实话实说。小日本不小。